Objective: To determine cytomegalovirus reactivation in hematopoietic stem cell transplant patients with haploidentical versus fully HLA matched donors. Methods: We enrolled 60 patients in this retrospective observational study at Armed Forces Bone marrow transplant centre (AFBMTC) between March 2019 and October 2022. CMV DNA PCR was done weekly from day +14 to day +100 to monitor CMV reactivation during the 100-day post-HSCT period. An Applied Biosystems 7500 real-time PCR machine was used to conduct the PCR analysis. Results: The median age was 15+10.6 years. 39(65%) patients had CMV reactivation. The median time to CMV DNAemia was 19.25 days. 2 out of 39 patients received ganciclovir, while 26 (43.3%) received valganciclovir. The underlying diagnosis had statistically significant correlation with CMV reactivation (p =0.02). Primary graft failure was the most frequent cause of mortality, resulting in neutropenic sepsis in 6 patients (42.85%), but 3 of these patients also had CMV reactivation. The overall survival (OS) was 76.7% and disease-free survival (DFS) was estimated at 71.7%. Neither OS nor DFS in our analysis showed a statistically significant correlation with CMV infection. Conclusion: This study demonstrated a statistically significant association between haploidentical transplant and CMV reactivation, compared to fully matched recipients. Various factors, including underlying diagnosis, conditioning regimen, and GVHD prophylaxis, were also found to be correlated with CMV reactivation. However, while CMV reactivation was associated with specific factors, it did not impact overall survival or disease-free survival in the study population.